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The authors consider acute problems in the quality and management of medical services challenging health care
systems worldwide. This actuality has motivated the representatives of the European Association for Predictive,
Preventive and Personalised Medicine and European Federation of Clinical Chemistry and Laboratory Medicine to
consider the efforts in promoting an integrative approach based on multidisciplinary expertise to advance health
care. The current paper provides a global overview of the problems related to medical services: pandemic scenario
in the progression of common chronic diseases, delayed interventional approaches of reactive medicine, poor
economy of health care systems, lack of specialised educational programmes, problematic ethical aspects of
treatments as well as inadequate communication among professional groups and policymakers. Further, in the form
of individual paragraphs, the article presents a consolidated position of the represented European organisations.
This position is focused on the patients' needs, expert recommendations for the relevant medical fields and
plausible solutions which have a potential to advance health care services if the long-term strategies were to be
effectively implemented as proposed here.
Keywords: Laboratory medicine, Predictive preventive and personalised medicine, Integrative medical record,
Health care, Patient in focus, Bioinformatics, Economy, Ethics, Education, Expert recommendationsAdvancing the health care paradigm
For many acute and chronic disorders, the current health
care outcomes are considered as being inadequate [1].
Current health care practices essentially rely on the emer-
gence of signs and symptoms of human pathologies prior
to initiation of interventional modalities as illustrated in
Figure 1A. Consequently, despite high costs associated
with the absolute majority of currently administrated med-
ical services, long-term morbidity and prognosis may often
be poor. This is due to inadequate control of disease mani-
festations, treatment failure, disease recurrence and the ap-
pearance of severe secondary complications contributing* Correspondence: Olga.Golubnitschaja@ukb.uni-bonn.de
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distribution, and reproduction in any mediumto relatively low quality of life for the treated persons and
high mortality. Examples of this pessimistic perspective in-
clude the pandemic of type 2 diabetes mellitus, neurode-
generative disorders and some types of cancer, which, over
the next 10–20 years, associated with the economic situ-
ation, could spell disaster for health care systems on a glo-
bal scale.
A desirable strategy is illustrated in Figure 1B. The
major premise of the advanced health care approach is
the paradigm change from reactive to predictive medi-
cine, from delayed to preventive and personalised medi-
cine. Since chronic pathologies are generally triggered at
the molecular level with consequent symptomatic mani-
festation of the disease, a laboratory-based detection of
pathology-specific molecular patterns would create a
well-founded basis for the desirable predictive medical
services giving the opportunity for optimal health care.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Figure 1 Current health care approach (A) versus advanced health care approach (B). The advanced health care approach considers a
paradigm change from delayed interventional to predictive, preventive and personalised medicine as the robust platform for optimal medical
services; figure is taken from [1].
Figure 2 Worldwide prognosis of the pandemic increase in the
incidence of the T2DM. (*) Estimations as published around the
year 2000. (**) Worsening prognosis as published in 2003–2008.
Current prognosis is marked in red colour; data taken from [3].
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gies to predict human pathologies, the devising of appro-
priate and timely preventive strategies and individualised
treatment planning.
Multidisciplinary analytical expertise is essential
for accurate diagnosis and optimal clinical
decisions: stakeholders in the board
Optimal clinical decisions are the result of a multidiscip-
linary approach that might be viewed as a board of spe-
cialists with complementary analytical expertise. Accurate
diagnosis and treatments tailored to the person are ex-
tremely challenging which drives the development of
emerging technologies and harnesses them for the delivery
of the requisite medical services. Therefore, the overall
task is formulated as the integrative medical approach of
the multimodal diagnostics, disease-specific biomarker
patterns, individual patient profiles, creation of medical re-
cords and treatments tailored to the person [2].
Multimodal diagnostics represents a model-based
examination procedure with several levels of examin-
ation resulting in extended patient profiles and medical
records which obligate inclusion of an interview with
the patient / a questionnaire filled in for relevant infor-
mation on any known pathology, medical imaging,
laboratory diagnostics and evaluation of relevant risk
factors. For laboratory diagnostics, it is highly recom-
mended to use minimally invasive validated blood tests for
the detection of stage-specific molecular patterns at com-
plementary levels of targeted regulation (DNA polymor-
phisms, transcripts, protein expression, post-translational
modification, stage-specific subcellular imaging, shifted
enzymatic activity etc.).The central role of laboratory medicine as the
integrating element in health care services
It is statistically evidenced that, currently, about 70% of
all medical interventions utilise laboratory data. How-
ever, this number is expected to rise since, without any
exception, all medical fields request robust information
from the laboratory to make well-justified clinical deci-
sions. For example, this is the case in (pre-)diabetes care.
The pandemic increase in the incidence of type 2
diabetes mellitus (T2DM) year by year is getting worse
as demonstrated in Figure 2, and the overall number of
diabetic patients is expected to double over the next two
decades. Due to the high prevalence of the pathology
and severe chronic complications, the application of pre-
dictive diagnostics, targeted preventive measures and
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to advance (pre-)diabetes care. This improvement would
minimise subsequent complications and associated costs.
The principal difference between the current and highly
desirable (pre-)diabetes care is the progress from the unsat-
isfactory reactive to the predictive and preventive medical
services by innovative technologies of laboratory medicine
applied at the (pre-)clinical disease stages as follows [3]:
1. First level. Prediction of the familial predisposition,
targeted prevention of T2DM early in childhood.
2. Second level. Prediction of early/premature ageing
and targeted prevention of T2DM pre-stages.
3. Third level. Prediction of secondary complications in
the cohort of T2DM patients and creation of
treatments tailored to the patient to prevent
cardiovascular, neurodegenerative and cancer
diseases frequently developed in diabetic patients.
The common onset of T2DM in early adulthood leads
to dramatic consequences linked with the early onset of
diverse severe complications such as retinopathy, ne-
phropathy, polyneuropathy, dementia, silent ischaemia,
‘diabetic foot,’ endometrium carcinoma and other types of
cancer. Chronic degenerative processes affecting vital or-
gans in T2DM usually appear as a ‘domino effect’ in the
characteristic sequence as reviewed earlier [4], thereby
considering an actively proliferating diabetic retinopathy
to be an early indicator of an individual predisposition to
the cascade of severe chronic complications developing
downstream towards the manifestation of highly prolifera-
tive retinopathy. A highly proliferative process in the ret-
ina is characterised by pathology-specific molecular
patterns which may be detected utilising predictive blood
tests some years before the clinical manifestation of the
pathology [5]. In this context, the central role of laboratory
medicine is to interconnect the relevant medical fields as
the integrating element in health care services. In the case
of (pre-)diabetes care, laboratory medicine is interrelated
to general practitioner/family practice, diabetology, radi-
ology, ophthalmology, endocrinology, gynaecology, sport
medicine, professional nutrition etc.
Shifting of competencies and responsibilities in
the laboratory-clinician interface
Shifting the role of laboratory from the ‘passive performing’
to the ‘active advising’ is the next paradigm change in
health care. This reconsideration of the laboratory-clinician
interface might significantly advance the quality of current
medical services, although the implementation of this
approach across countries should be adapted to local
conditions. Well-known motivating actualities for the re-
consideration are, for example, so-called within-individual
variations as well as grey-zone results, when individuallaboratory parameters range between ‘healthy’ and ‘un-
healthy’ zones and any interpretation is rather problematic.
Therefore, recommendations by the laboratory to as-
sist clinical practice are highly desirable [6]. This assist-
ance ranges from advising on the necessity for additional
tests to the dynamic analysis of the targets. Additional
tests should be considered from the viewpoint of their
reasonability, in order to reach an accurate and realistic
health-related data interpretation for the individual. The
analysis of dynamic changes of the target is essential to
evaluate potential health impacts such as an individual
predisposition to the disease and/or a predictive diagno-
sis before a clinical manifestation of symptoms. Labora-
tory value-added investigation and interpretation should
be obligatory in creating an advanced functional rela-
tionship between laboratory medicine and clinicians to-
gether as the responsible decision-makers [7].
Predictive/prognostic laboratory tests as the
robust platform for targeted prevention and
treatments tailored to the person
The following actualities motivate the introduction of




 Overdosed and poisoned patients
 Ineffective treatments
Current deficits in medical services such as missing
toxicological examination of the prescribed medication
and ethically problematic delayed and inadequate treat-
ments require new strategies for a targeted prevention
and more effective treatments tailored to the person [8].
Validated predictive and prognostic laboratory tests pro-
vide new perspectives on how to improve diagnostic and
prognostic performances. In order to create a robust in-
vestigative platform, the utilisation of appropriate labora-
tory tests should be mandated, which means that an
extensive collaboration between laboratory professional
organisations on one side and policymakers on the other
side as soon as practicable to intensify the process.
Accuracy, sensitivity, specificity and unification of
analytical tests: status quo and future perspectives
The above requirements lead to obligatory prioritising of
the improved analytical tests which might be utilised in
order to advance medical services today, in the near
future but certainly in the long-term perspective. The
undoubted criteria are the following:
1. Diagnostic sensitivity,
2. Diagnostic specificity,
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4. Unification.
Traceability of a measurand to a certified reference ma-
terial and measurements validated by a definitive analytical
method leads to the ‘unification’ of a given laboratory
test. There is the evident necessity to enable globally
comparable investigative, diagnostic and prognostic strat-
egies to be reliably implemented. This requires regula-
tory oversight and meaningful engagement with in vitro
diagnostic providers. The globalisation of markets and
laboratory-related business requires the comparability,
or the unification, of laboratory test values. The mobility
of both patients and health care professionals as well
as the increasing global data flow require such com-
parability [9]. Hence, the unification of laboratory tests
should be placed at the top of the list of correspond-
ing adapting measures.
Disease monitoring, self-monitoring and
distanced monitoring
Current trends in Europe demonstrate dramatic demo-
graphic shifts in favour of elderly subpopulations followed
by the consequent alterations in the overall profile of the
patient cohorts. With type 2 diabetes mellitus, pandemic
and its severe secondary complication such as stroke, 50%
of people after 85 years of age affected by Alzheimer's
disease (also diagnosed as type 3 diabetes) and neurode-
generative eye diseases with leading causes of blindness,
diabetic retinopathy and estimated 70 million glaucoma
patients worldwide, millions of patients with Parkinson’s
disease, multiple sclerosis, epilepsy and dementia in the
elderly—altogether dramatically affect life quality and
social and economic indexes of populations around the
globe. According to the current prognoses, it is predicted
that neurodegenerative disorders will achieve more than
30% of the global disease burden till 2025 [10]. These
realities require new strategies in health care in terms
of long-term monitoring of chronically diseased patients
with a potential duration of some years to several de-
cades of life [11]. A new generation of ‘point-of-care’
monitoring devices is required. These mobile health
technologies must enable both the remote management
of the analytical process and the active engagement of
laboratory professionals at the clinical level.
Promotion of the concepts of ‘participatory’
medicine: improving health knowledge and
health language in the general population and
collaboration with organised patient groups
‘Nothing about me without me’ is an excellent slogan of
the Society of Participatory Medicine [12] which certainly
should be broadly accepted by advanced medical services.
A number of independent evidence-based studies havedemonstrated that the efficacy of treatments strongly
depends on the level of harmony in ‘doctor-patient’ col-
laboration. However, the critical question remains: how
can a common language that is understandable for the
professionals in the health care industry and patients be
created? The only solution is high didactic quality edu-
cational measures aiming at significant improvements
of health knowledge and health language in the general
population. Unfortunately, information retrieved from
the internet is frequently of poor professional quality
providing controversial data that confuse the under-
standing and slow down the learning process of laymen.
People need to be advised of reliable information sources
that are well adapted to a corresponding level of under-
standing (categories of children, youth and adults) and
concrete interests of subpopulations (level of education,
groups of professionals, patient cohorts). In the field of
education, laboratory medicine may play a leading role
providing up-to-date information that is accessible to the
layman on laboratory tests and their interpretation for
individual health and disease conditions. A professional
version will enable for a detailed knowledge about bio-
active molecules, enzymatic reactions, molecular and
cellular processes which underlie the pathomechanisms
of individual predispositions and pathologies as well as
medical treatments. These innovations along the tight
collaboration of organised patient groups are one of the
strongest instruments of a more effective knowledge
promotion [13].
Are ‘more laboratory tests’ equal to ‘better life
quality’? Economy and ethics of personalised
medicine—patient in focus
The well-known problem of the intensity of medical ser-
vices in general and a reasonable number of laboratory
tests to be performed in individual cases in particular
should be considered in the context of the economy of
personalised medicine (how much?) on one side and
the ethical issue (is it good enough?) on the other side.
However, the middle point between both factors under
consideration should be an obligatory recognition of the
long-term welfare of the patient [7]. An optimal evaluation
of the individual contributing factors enables ethically
correct and economically justified clinical decisions.
However, currently, no one is able to estimate all the
genetic, epigenetic, lifestyle-dependent, environmental,
nutritional factors in an individual to provide the level
of recommendations and adequate prognostication.
Creation of innovative medical records: a ‘happy
marriage’ with integrative bioinformatics in the
near future
How can integrative analytical data in the above-delineated
context and for the listed purposes be treated? A creation
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priority for scientific programmes of multidisciplinary char-
acter. Indeed, corresponding budgets are currently under
extensive discussion for the new European programme in
preparation for personalised medicine, the ‘Horizon 2020’
[14]. An integrative bioinformatics is considered as the
powerful tool to fulfil this highly ambitious task since it be-
comes essential to the following:
 Gathering of complex data received from emerging
technologies, such as medical imaging,
pharmacogenetics, clinical ‘-omics’, pathology-
specific molecular patters, disease modelling and
individual patient profiles
 Undertaking both retrospective and prospective
analyses of biodata, information and knowledge
related to the (epi-) genome and its links to disease
for translational medicine
 Providing help with information and knowledge to
advance health-related sciences and to make health
care services more reliable
 Analysing complex technological inputs for making
optimal clinical decisions
 Learning from what has happened at the individual,
process and health system levels to promote the
integrative approach by predictive, preventive and
personalised medicine (PPPM)
 Creating patient records and securing safety
treatment of patient databases
 Promoting standardisation in health care
 Presenting integrated data innovatively to enhance
comprehension
Creation of innovative medical records might be a
strong driver for standardising communications in the
broader health-related scientific community and health
care industry [14,15].
Progressing from ‘disease care’ to ‘health care’:
‘well-being’ concept—what is beyond the issue?
The evident pandemic of common chronic diseases, the
consequences of a reactive approach and hence poor
economy of disease care as well as dramatic social and
ethical problems that resulted from delayed medical ser-
vices necessitate experts to reconsider the current
paradigm of reactive medicine in favour of the macro-
economic, more efficient predictive and targeted pre-
ventive measures. This means that there is a mandated
progressive implementation of a new philosophy of the
well-being concept tailored to the person (age, gender,
socio-economic status, individual predispositions, patient-
specific profile etc.) as a carefully elaborated spectrum of
measures for professional care that promotes the mental
and physical health of an individual [8].Which among the new services might be introduced
in order to promote the implementation of the well-
being concept? It will be based on the individualisation
of analytical evidence of individuals' interaction with
their environment and the impact of avoiding or mitigat-
ing its environmental exposure on wellness. Sufficiently,
better individual outcomes are expected with respect to
less morbidity and a better quality of life. Herewith, la-
boratory medicine is considered an essential contributor
to such assessments, leading to a hope for both im-
proved health economy and ethical standards [16,17].
Towards the question of who may benefit from
patient records: sensitive ethical aspects behind
PPPM
From what was mentioned previously, it is getting clear
that the innovative technologies of multidisciplinary
analysis summarised by comprehensive patient records
provide the complete information about current pathology-
specific profiles and potential predispositions of the
person. This reality creates a number of socio-economic
questions and concomitant ethical issues such as the
following:
 Who is allowed access to individual records in the
database?
 Is the current technological platform robust enough
to guarantee authorised access only and to secure
the rights of the patient and specialised PPPM
centres?
 Who is authorised to interpret these individual
records?
 What are the expected and potential long-term
consequences of the record for the patient: health
benefits versus potential danger of data misuse?
 How well are the patient's interests and specialised
centre defended for optimal PPPM performance in
the society? Is the juristic platform robust enough or
does it need to be extended?
Robust information governance of the database and
high quality of ethical standards are the prerequisites for
the successful implementation of PPPM in health care
systems [18].
Biobanking: meaning, optimal organisation and
perspectives in a global scale
Ethically correct and technologically excellent bio-
preservation and biobanking are central activities in the
field of PPPM. This was formulated in the EPMA White
Paper in 2012 [13].
Internationally valid biobanking is happening now. For
that, a list of essential requirements should be func-
tionally satisfied. Competencies should be harmonised
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community and health care providers which includes
commercial companies interested in in vitro diagnostics,
development of new biomarkers and novel drug targets.
The following unsolved questions remain:
 How can local and international barriers be broken
down to unify international biopreservation
technologies, sample collections and databases?
 Who carries the role to promote in the process of
biobanking internationalisation?
 Who should cover the costs of the internationally
accessible systems?
 Who is allowed to legally use these international
biobanks once they are created?
 Who could be nominated as the end user of the
data collected?
Currently, biobanking is facing major viability challenges.
As for individual types of biological material (tissue sam-
ples, blood samples, DNA, RNA, proteins, metabolites
etc.), national laws vary for local instructions and legal ap-
proaches and how samples may be collected, stored, re-
trieved and tested. In plenty of cases, this may be quite
restrictive and incompatible with rules that are legal for
other countries. The analytical quality of collections is fre-
quently compromised as the storage condition for the sam-
ples is changing. Donation of samples to a biobank not
only requires anonymity but also strict control over record
linkage and access. Sample collections with a permission of
specialised ethical commission should be hosted by viable
academic units and health facilities with a proven record of
research and should not be exploited for commercial gain
but for the common good. Disease-focused collections re-
quire acquired samples to be retrospectively valid for a de-
velopment of novel biomarkers. Such biomarkers need to
have a demonstrated clinical utility prior to their introduc-
tion in medical services. For a disease-specific biobanking,
the disease needs to have been well characterised for each
patient, with immaculate record-keeping, to enable to draw
conclusions on the new markers.
These critical problems may be optimally solved by
relevant professional groups with complementary ex-
pertise such as the European Federation of Clinical
Chemistry and Laboratory Medicine, EPMA and ESBB
followed by adequate decisions of policymakers resulting
in the creation of a robust juristic platform. An inter-
national biobanking, if designed as being reliable for
advanced health care services, needs an adequate juristic
platform that considers the following interests of all
parties involved in the research and business:
1. Donors of biological materials,
2. Clinicians providing patient records,3. Laboratory units collecting the samples,
4. Storage units,
5. Research analysing the collections and creating new
diagnostic and drug targets,
6. Patenting institutions,
7. Health care industry,
8. Patient cohorts,
9. Groups at risk,
10. General population and
11. Educators.
Forcing the practical application of novel
molecular targets, specific biomarkers and more
efficient laboratory tests
Current calculations demonstrate a long-term trend of
the dramatic crisis in the creation of clinically useful
molecular entities (biomarkers, drug targets etc.). Al-
though the graph presented in Figure 3 holds for the ori-
ginal producers of potential molecular targets, within
the horizon of 10–15 years, the same problems may be
predicted for and confronted by the generic companies.
Further, an innovation in in vitro diagnostic testing is
hampered by a lack of funding for studies aiming at the
effective validation of the clinical utility of novel bio-
markers. Not only is there a need for meaningful health
technology assessments but also a need to remove
supplanted markers to minimise financial wastage that
could otherwise be better spent. Consequently, a deep
analysis of currently unfavourable situations followed by
the creation of potential ways of how to shorten the time
span between a discovery of new molecular targets and
their effective utilisation in daily practice is the strategic
point of highest priority [19]. Up to this point, expert
recommendations have been summarised in the EPMA
White Paper in 2012 [13]. The proposed measures in-
clude the following:
 Emerging technologies in population screening
(faster, more precise, cheaper)
 Set-up of pathology-specific biomarker patterns
instead of ineffective single molecules
 Non- or minimally invasive diagnostic tools (saliva,
urea, blood etc.)
 Effective promotion of validation studies
 Transparent schemes for functional contacts
between researchers who discovered new targets
and implementing industrial partners
 Dramatic improvements in national and
international patenting systems
An effective implementation of the above-listed mea-
sures may favour more flexible small- and middle-sized
industrial companies in the competitive process of
PPPM-related innovation.
Figure 3 R&D expenditure versus new molecular targets as observed in industrial developments in 1997–2007 [20]. NME, new molecule entity.
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ation of current investments should be performed.
Hence, having clinical trials that are costly and usually
recreated for every new marker is a typical example of
wasting money. In contrast, the creation of consolidated
laboratory networks of equivalent standards to accelerate
clinical validation across the countries of the European
Union represents the optimal way on how to generate
sufficient professional power in an economically reason-
able approach. Therefore, further consideration of these
two crucial steps in the overall process to advance health
care is essential:
A. Consolidation of professional efforts and
B. Standardisation of healthcare services in the Europe.
See the following sections for details.
Consolidation of professional groups involved in
health care sciences and services
Status quo
Currently, any multidisciplinary meeting and collaboration
of professional groups related to health care usually are re-
sults of an enthusiastic initiative of single groups who real-
ise that a multidisciplinary consolidation is the only way
on how to advance actual knowledge and services.
Improved approach
Consolidation of professional groups involved in health
care sciences and services is a multifunctional task
which should be performed at several levels of activities:
 Mandated optimal set-up of multidisciplinary
stakeholders in diagnostics and in the prevention
and treatment of individual pathologies Regular meetings of stakeholders with
multidisciplinary expertise motivated and regulated
by health care-related national and international
programmes
 Multifunctional education as an obligation for
related professional groups
 Creation of optimal economic conditions motivating
a multidisciplinary expertise to be applied in health
care sciences and services
Standardisation of health care services in Europe:
how to proceed
This is a strategic issue for policymakers after detailed
consultations with health care professionals. In order to
effectively promote medical services, we need much
more harmonisation as has been currently observe in
health care across Europe. The process of harmonisation
requires clear focuses and should result in reasonable
standards introduced for comparable/analogous func-
tional elements and systems. All of the existing systems
should be carefully analysed at the European level before
corresponding standards may be elaborated and intro-
duced in daily medical practice. European standards
have been recommended by experts.
The European standards recommended for analytical
systems are as follows:
 Consistent standards of laboratory practice
 Conformance with all relevant ISO/CEN standards
 Equivalent units of measurement
 Traceability of the measurand
 Equal quality of measurements
 Equal reference systems
 Equal evaluation systems
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electronic patient record are as follows:
 Mandated multidisciplinary examination approach
 Unified communication protocols for data exchange
between different information systems in health care
 Consolidated algorithms
 Standardised and complex interpretation of
analytical results
It is obvious that these listed measures are tasks super-
ior to the national level. This may be effectively achieved
if corresponding European resources will be adequately
mobilised, including consolidated professional efforts
and dedicated budgets.
Professional education: meaning and instruments
Professional groups involved in health care-relevant re-
search and services realise step by step that they speak ‘dif-
ferent professional languages’ that are less understandable
for other related branches. Consequently, great discoveries
made/innovations triggered by one professional group are
frequently underestimated, or even not valued at all, by
other experts, thus resulting in delays in the implementa-
tion of novel developments in medical branches. There-
fore, we need to develop a new culture among experts in
order to promote the multidisciplinary character of pre-
dictive, preventive and personalised medicine and con-
comitantly to advance currently deficient health care
services. Herewith, the authors present a consolidated
position to the point made as follows: the innovative
PPPM-related educational programmes for professionals
should be prioritised in the Common Strategic Framework
(also called as the New European Framework Programme
Horizon 2020) as well as by other global and topic-
relevant national programmes [14].
In order to promote innovative educational programmes,
the following worldwide pioneer initiatives have been
developed to create didactic materials for traditional
and innovative medical fields:
1. Since 2010, The EPMA Journal (open access, PubMed
indexed) regularly updates both needs and
achievements in the field of PPPM applied to
common and rare pathologies [21]. The following
topics are treated by the journal:
 Health care overview in European countries and
worldwide
 PPPM applied to common diseases such as
diabetes mellitus, cardiovascular disease, cancer
and neurodegenerative disorders
 PPPM in rare diseases
 PPPM in dentistry
 Frequent syndromes and groups at risk Reproductive medicine
 PPPM in pregnancy, neonatology and paediatrics
 Body culture, individualised exercise training,
nutrition and doping control
 Evidence-based traditional and alternative
medicine
 Integrative bioinformatics, patient records and
disease modelling
 Treatments tailored to the person
 Validation, standardisation and economic,
ethical, legal, social and other relevant aspects of
PPPM2. In 2012, Springer has launched a new book series
entitles Advances in Predictive, Preventive and
Personalised Medicine in collaboration with the
European Association for Predictive, Preventive and
Personalised Medicine [22]. The first volume in the
series, Healthcare Overview: New Perspectives (edited
by V. Costigliola) has been released in October 2012.
Approximately three books will be published each
year.
The book series Advances in Predictive, Preventive
and Personalised Medicine provides an overview of
multidisciplinary aspects of advanced biomedical ap-
proaches and innovative technologies in health care.
Topics focus on cost-effective management tailored to
the person in health and disease, and innovative strat-
egies for standardisation of health care services. The
book series also includes new guidelines for medical eth-
ics, innovative approaches to early and predictive diag-
nostics, targeted prevention in healthy individuals, and
health care economy and marketing. Innovative predict-
ive, preventive and personalised medicine is emerging as
the focal point of efforts in health care aimed at curbing
the prevalence of common (diabetes mellitus, cardiovas-
cular diseases, chronic respiratory diseases and cancer)
and rare diseases. This new book series is intended to
serve as a reference source for researchers and the
health care industry with special emphasis on health
promotion in the general population.
Political regulations to advance health care systems
Through the support of the Alexander von Humboldt
Foundation (Prof. Dr. Lotta Salminen of Finland and the
host supervisor Prof. Dr. Olga Golubnitschaja of
Germany were awarded fellowship), in the years 2012–
2013, EPMA has performed a specialised project focused
on the collaboration among PPPM-related professional
groups and policymakers. This project is aimed to iden-
tify problems and deficits in health care of common and
pandemic chronic diseases such as type 2 diabetes
mellitus. Interviews performed with the experts from all
countries of the European Union, Israel, Russia and
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common deficits is missing communication and collabor-
ation between health care professionals and decision-
makers. Moreover, there are difficulties in accessing
national regulatory bodies to enhance the message of
patient-focused health care. This evidence demonstrates
that decisions in the health care sector are generally made
without consideration of accumulated professional know-
ledge. This may explain the lack of sufficient efficacy cur-
rently observed in health care systems. The completed
report with the collected data that resulted from this pro-
ject is currently prepared for publication in The EPMA
Journal (2013).
In contrast, if well established, the collaboration with
governmental institutions may lead to the crucial recon-
sideration of current national and European guidelines
for health care-relevant research activities and medical
services. There are following emerging issues to be
reconsidered in health care:
1. Promoting research fields focused on the patient
needs
2. Mandating a paradigm shift from reactive to
predictive and preventive medicine
3. Creating specialised state budgets to target
preventive measures against pandemic incidence of
common chronic diseases
4. Forcing an effective implementation of innovative
predictive diagnostics
5. Creating new educational programmes for
professionals to implement integrative medical
services in predictive, preventive and personalised
medicine
6. Creating educational measures to increase the
understanding of innovative diagnostic technologies
and targeted preventive measures in the general
population
7. Creating new economic models to motivate health
responsibility.
As health care is subject to national subsidiarity, there
are substantial variations in the level of provision in differ-
ent countries. However, corresponding standards might
be introduced at the European level to promote inter-
European mobility and to avoid economic discrepancies
and conflict of interest [23].
Summary
An integrative medical approach to advance health care
services is a multidisciplinary task that covers well-
harmonised international efforts in research, business
and politics. In this article, a consolidated position of
the European Federation of Clinical Chemistry and
Laboratory Medicine and European Association forPredictive, Preventive and Personalised Medicine is
presented. The authors have identified the priorities
which might effectively navigate the overall process of
the professional consolidation and quality promotion in
the field. In order to realise the proposed initiatives, the
undersigned organisations consider the creation of the
working group of experts as the follow-up action to
work out common strategies and to elaborate corre-
sponding structures, scientific proposals and recom-
mendations for the European standards.
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